By clicking "Accept," you confirm: Your selection is stored locally and may be recorded for compliance purposes
The two datasets converge on the same point: much of what DXA labels as lean-mass loss on a GLP-1 is liver tissue responding to metabolic disease, not muscle responding to the medication
Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I
Its promising, for sure, but I think its way too early to say This drug is going to help reduce risk of AMD. The authors also noted that they could not fully account for factors such as medication adherence, dosage, or detailed disease staging
High dimensional multi-omics reveals unique characteristics of early plasma administration in polytrauma patients with TBI
Updated: Willian Hao Syuen Ng, Medical Student, University of Newcastle, Newcastle, Australia